

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Mingyuan Medicare Development Company Limited (the “Company”) dated 14 January 2011 in relation to the Distribution Agreement with Shanghai Pharmaceuticals Co. Ltd. (the “Announcement”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement, unless the context otherwise requires.

The directors of the Company have come to notice that due to oversight, the information in relation to the total number of C-12 and HPV sold in 2009 and first half 2010 should be 3.25 million and 1.76 million respectively.

By order of the Board
Mingyuan Medicare Development Company Limited
銘源醫療發展有限公司*
Kenny Poon
Company Secretary

Hong Kong, 17 January 2011

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Iu Chung, Mr. Hu Jun, and Mr. Yu Ti Jun; the non-executive directors are Mr. Yang Zhen Hua and Mr. Ma Yong Wei; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua and Mr. Lee Sze Ho, Henry.

* *For identification purposes only*